Prime Medicine, Inc.
Alpha-1 Anti-trypsin Deficiency (AATD)
Alpha-1 Anti-trypsin Deficiency
Resolved
7days ago
FDA decision · ~ Jun 30, 2026 estimated
What's at stake
The FDA's approval decision on Alpha-1 Anti-trypsin Deficiency (AATD) for Alpha-1 Anti-trypsin Deficiency is due ~ Jun 30, 2026. A green light opens the market; a complete response letter (CRL) usually sinks the stock.
Primary source
· SEC 8-K
verified 14h ago
“Prime Medicine expects to file an IND and/or CTA for its AATD program in mid-2026,”